neuropsychologists

infusion

Therapeutic Plasma Exchange Technology Useful for MG Treatment

The use of a novel nanomembrane-based therapeutic plasma exchange (TPE) has been shown to reduce prolonged invasive mechanical ventilation (IMV) during acute exacerbations in patients with myasthenia gravis (MG), according to a new study published in the Journal of Clinical Medicine. A single-center, retrospective, and before-and-after study were conducted among patients with MG with impending…

thymus gland

Study Highlights Surgical Outcomes Among Patients With Thymoma and MG

In patients with myasthenia gravis (MG) and those without the disorder, postsurgical complications following thymoma do not differ, according to the results of a study that was published in Asian Cardiovascular and Thoracic Annals. The researchers sought to explore the impact of MG among patients with thymoma undergoing surgery. A total of 145 consecutive patients…

Demyelinated nerve

New Study to Identify Biomarkers in MS Lesions Now Enrolling Patients

Rune Labs is enrolling patients with multiple sclerosis (MS) in a study that aims to identify neurophysiological biomarkers of the disease, according to a press release from the company. During the study, demyelination, a hallmark symptom of MS, will be measured using a closed loop technology. “By taking advantage of access to the spinal cord…

EMA Accepts Marketing Authorization of Natalizumab Biosimilar for MS

Polpharma Biologics of Amsterdam, Netherlands, an international biotech company, announced that the European Medicines Agency (EMA) accepted a Marketing Authorization Application (MAA) for biosimilar natalizumab, a monoclonal antibody treatment for adults with highly active relapsing-remitting multiple sclerosis (RRMS). Natalizumab is a proposed biosimilar to Tysabri®, and the application was for intravenous administration at the same…

New Blood Test Predicts Disease Progression in MS

Neurofilament light chain (NfL) is a new and easily accessible blood test that could predict disease progressions of several neurodegenerative diseases, such as multiple sclerosis (MS), Parkinson’s disease, and Alzheimer’s Disease, according to a recent press release by LabCorp. The principle behind the test is that Neurofilament release is a known consequence of neuronal destruction.…

exercise equipment

Study Identifies Lifestyle Factors Related to Disease Progression in MS

A variety of lifestyle factors are correlated with disability progression in patients with multiple sclerosis (MS), according to a study published in Multiple Sclerosis and Related Disorders. The researchers found that lifestyle factors including physical activity, arterial hypertension, being overweight/obese, the use of lipid-lowering drugs, and cognitive reserve were all related to the accumulation of…

Plasmapheresis as an Effective Therapy for NMOSD, MS, and MG

Patients with neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and myasthenia gravis (MG) showed significant improvements after treatment with plasmapheresis, according to results from the Japan-Plasmapheresis Outcome and Practice Patterns Study published in Therapeutic Apheresis and Dialysis. Statistically significant improvements in the modified Rankin Scale (mRS) and Barthel Index scores were reported for patients…

cognitive function

Early Ozanimod Treatment Linked With Improved Cognition in MS

Early use of ozanimod (Zeposia®) was found to improve or preserve cognitive function in patients with relapsing multiple sclerosis (MS), according to a new post hoc analysis from the phase 3 SUNBEAM trial (NCT02294058) and the phase 3 open-label extension (OLE) DAYBREAK trial (NCT02576717). The analysis showed that the greatest treatment effect was observed in…

Nabiximols Oromucosal Spray Fails to Meet Primary Endpoint in MS Trial

Nabiximols oromucosal spray, an experimental treatment for multiple sclerosis (MS) spasticity, failed to meet its primary endpoint in the RELEASE MSS1 (NCT04657666) phase 3 clinical trial, according to a press release from its developer, Jazz Pharmaceuticals. During the trial, patients did not meet the primary endpoint of a significant change in Lower Limb Muscle Tone-6,…

Next post in MS News Briefs